Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01592786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
August 31, 2013
Enrollment
906 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

asperger's, asperger's disorder, autism, autism spectrum disorder (asd), autistic disorder, pediatric autism, pervasive developmental disorder not otherwise specified (pdd-nos)